一分钟看懂
这是一项关于淋巴瘤的I 期研究，登记的药物或干预包括Rocbrutinib；Rituximab；Cyclophosphamide；doxorubicin；Vincristin；Prednisone，当前状态为研究进行中，已停止招募。登记地点显示中国广州有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Rocbrutinib；Rituximab；Cyclophosphamide；doxorubicin；Vincristin；Prednisone · I 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Sun Yat-sen University Cancer Center · 广州
公开的入选条件
- * Participants was histopathologically diagnosed with any of the following diseases: DLBCL, MZL or MCL (if enrolled in the dose expansion phase, histological confirmation of non-GCB subtype), and have not previously received anti-tumor systemic therapy or loca
- * Participants must have at least one measurable lesion.
- * ECOG physical status score 0-2.
- * Life expectancy ≥6 months.
- * International Prognostic Index (IPI) score ≥ 2 (only participants with DLBCL in dose expansion portion).
- * Adequate coagulation, liver, kidney, and hematopoietic functions：PT and APTT \<1.5x ULN; serum bilirubin \<1.5x ULN except in participants with Gilbert's syndrome who must have a serum bilirubin of \<3x ULN, AST and ALT ≤ 3x ULN or \< 5x ULN if hepatic invol
- * Women of childbearing potential must have a negative serum or urine (beta-human chorionic gonadotropin \[beta-hCG\]) at screening.
- * Women of childbearing potential and men who are sexually active with a woman of childbearing potential must be practicing a highly effective contraceptive measures of during and after the study (90 days after the last dose of ROCBRUTINIB and 12 months after
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06251180；登记信息更新于 2026-09-11。